Showing results (261-270 of 277) with videos related to

Sort By:
Pageof 28
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 28, 2023
ROSEWOOD: A Phase II Randomized Study of Zanubrutinib Plus Obinutuzumab Versus Obinutuzumab Monotherapy in Patients With Relapsed or Refractory Follicular LymphomaPier Luigi Zinzani, Jiří Mayer, Christopher R Flowers, et al.
American Journal of Hematology|August 30, 2023
Orelabrutinib for the treatment of relapsed or refractory marginal zone lymphoma: A phase 2, multicenter, open-label studyLijuan Deng, Zhiming Li, Huilai Zhang, et al.
Blood|January 10, 2023
Polatuzumab vedotin in previously untreated DLBCL: an Asia subpopulation analysis from the phase 3 POLARIX trialYuqin Song, Hervé Tilly, Shinya Rai, et al.
The Lancet. Oncology|December 13, 2023
Golidocitinib, a selective JAK1 tyrosine-kinase inhibitor, in patients with refractory or relapsed peripheral T-cell lymphoma (JACKPOT8 Part B): a single-arm, multinational, phase 2 studyYuqin Song, Luis Malpica, Qingqing Cai, et al.
Clinical Lymphoma, Myeloma & Leukemia|June 26, 2025
Health-Related Quality of Life With Odronextamab Monotherapy for Relapsed/Refractory Follicular Lymphoma in the ELM-2 StudyBenoit Tessoulin, James Harnett, Seok-Goo Cho, et al.
Nature Medicine|April 24, 2019
A safe and potent anti-CD19 CAR T cell therapyZhitao Ying, Xue F Huang, Xiaoyu Xiang, et al.
The New England Journal of Medicine|June 3, 2022
Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell LymphomaMichael L Wang, Wojciech Jurczak, Mats Jerkeman, et al.
The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.
Nature Communications|September 30, 2015
Expanding the biotechnology potential of lactobacilli through comparative genomics of 213 strains and associated generaZhihong Sun, Hugh M B Harris, Angela McCann, et al.
European Journal of Cancer (Oxford, England : 1990)|March 10, 2021
Dose escalation and expansion (phase Ia/Ib) study of GLS-010, a recombinant fully human antiprogrammed death-1 monoclonal antibody for advanced solid tumors or lymphomaDan Liu, Chunguang Ma, Ping Lu, et al.
Pageof 28